Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI ... resources are sufficient to fund its operations into Q1 2026. Total operating expenses were approximately $12.8 ...

Learn how accounts payable are recorded on a balance sheet, why they’re classified as liabilities and their role in managing ...

Exploring high dividend stocks with yields of 13-14% but potential risks, including the possibility of dividend cuts in the ...

Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha ...

Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical ...

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReS ...

Closed an Upsized and Oversubscribed $13 Million Public Offering to Fund Near-term Commercialization Milestones ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024, compared to a net loss of approximately $11.3 million, or $0.48 per ...

Marker Therapeutics was awarded a $2 million grant from NIH Small Business Innovation Research Program (SBIR) to support the clinical investigation of MT-601 in patients with lymphoma who have ...

Other Income: Other income for the third quarter ended September 30, 2024 was $193,000 compared to $706,000 for the same ...

New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response ...

WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter ...